Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa

Annals of General Psychiatry

Volumn 12, Issue 1, 2013, Pages

  Gorwood, Philip ^a,b   Burns, Tom ^c   Juckel, Georg ^d   Rossi, Alessandro ^e   San, Luis ^f   Hargarter, Ludger ^g   Schreiner, Andreas ^g  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b INSERM   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f HOSPITAL SANT JOAN DE DÉU   (Spain)

^g Johnson and Johnson Platz 1 ^*  (Germany)

Author keywords

Assessment; Functioning; Management; Psychiatrist; Schizophrenia; Survey

Indexed keywords

AFRICA; ARTICLE; CLINICAL ASSESSMENT; EUROPE; FEMALE; FUNCTIONAL STATUS; HUMAN; INTERVIEW; MALE; MIDDLE EAST; PERCEPTION; PHARMACEUTICAL CARE; PSYCHIATRIST; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SOCIAL INTERACTION;

EID: 84875344103     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-12-8     Document Type: Article

References (48)

1. Falkai P, Wobruck T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, . WFSBP Task Force on Treatment Guidelines for Schizophrenia World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6:132-191. 10.1080/15622970510030090, 16173147, WFSBP Task Force on Treatment Guidelines for Schizophrenia.
2. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008, 26:149-162. 10.2165/00019053-200826020-00005, 18198934.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, 297-313. Arlington: American Psychiatric Association, 4, American Psychiatric Association.
4. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372. 10.4088/JCP.v65n0312, 15096076.
5. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr Bull 2009, 35:300-306. 10.1093/schbul/sbn171, 2659311, 19126634.
6. Priebe S. Social outcomes in schizophrenia. Br J Psychiatry 2007, 191(Suppl 50):s15-s20.
7. Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007, 116:403-418. 10.1111/j.1600-0447.2007.01108.x, 17941964.
8. NICE: CG82 Schizophrenia (update): full guideline [http://guidance.nice.org.uk/CG82/Guidance].
9. Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, Nienhuis FJ, Walsh D. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000, 30:1155-1167. 10.1017/S0033291799002627, 12027051.
10. Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, Heaton RK, Laughren T, Leon AC, Mayo DJ, Patrick DL, Patterson TL, Rose A, Stover E, Wykes T. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull 2007, 33:805-822. 10.1093/schbul/sbl035, 2526156, 16931542.
11. Bond GR, Drake RE. Predictors of competitive employment among patients with schizophrenia. Curr Opin Psychiatry 2008, 21:362-369. 10.1097/YCO.0b013e328300eb0e, 18520741.
12. Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J, . CATIE Study Investigators Group Barriers to employment for people with schizophrenia. Am J Psychiatry 2006, 163:411-417. 10.1176/appi.ajp.163.3.411, 16513861, CATIE Study Investigators Group.
13. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry 2008, 21:630-639. 10.1097/YCO.0b013e328314e144, 18852573.
14. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 2006, 20(Suppl 6):57-61.
15. Ventura J, Subotnik KL, Guzik LH, Hellemann GS, Gitlin MJ, Wood RC, Nuechterlein KH. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 2011, 132:18-23. 10.1016/j.schres.2011.06.025, 3172347, 21764563.
16. APA: Practice guideline for the treatment of patients with schizophrenia, second edition; 2004 [http://psychiatryonline.org/index.aspx].
17. European Medicines Agency Draft Guideline 'Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia 2011, London: European Medicines Agency, European Medicines Agency.
18. Gorwood P, Peuskens J, . European Group On Functional Outcomes, Remission in Schizophrenia Setting new standards in schizophrenia outcomes: symptomatic remission 3 years before versus after the Andreasen criteria. Eur Psychiatry 2012, 27(Suppl 3):170-175. European Group On Functional Outcomes, Remission in Schizophrenia.
19. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharm 2010, 30:235-244.
20. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, . EUFEST Study Group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097. 10.1016/S0140-6736(08)60486-9, 18374841, EUFEST Study Group.
21. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009, 24:287-296. 10.1016/j.eurpsy.2008.12.002, 19195847.
22. Jang JH, Shin NY, Shim G, Park HY, Kim E, Jang GE, Kwon SJ, Hur JW, An SK, Kwon JS. Longitudinal patterns of social functioning and conversion to psychosis in subjects at ultra-high risk. Aust NZ J Psychiatry 2011, 45:763-770.
23. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161. 10.1016/j.schres.2006.09.012, 17092691.
24. Mortimer A, Martin S, Lôo H, Peuskens J, . SOLIANOL Study Group A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004, 19:63-69. 10.1097/00004850-200403000-00002, 15076013, SOLIANOL Study Group.
25. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull 2009, 35:347-361. 10.1093/schbul/sbn177, 2659313, 19176470.
26. Roder V, Mueller DR, Schmidt SJ. Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update. Schizophr Bull 2011, 37(Suppl 2):S71-S79. 10.1093/schbul/sbr072, 3160121, 21860050.
27. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Back AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 2012, 69:121-127. 10.1001/archgenpsychiatry.2011.129, 21969420.
28. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005, 187:131-136. 10.1192/bjp.187.2.131, 16055823.
29. San L, Ciudad A, Alvarez E, Bobes J, Gilaberte J. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry 2007, 22:490-498. 10.1016/j.eurpsy.2007.06.005, 17904337.
30. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001, 51:171-180. 10.1016/S0920-9964(99)00151-6, 11518637.
31. Lambert M, Naber D, Schacht A, Wagner T, Hundemer HP, Karow A, Huber CG, Suarez D, Haro JM, Novick D, Dittmann RW, Schimmelmann BG. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008, 118:220-229. 10.1111/j.1600-0447.2008.01213.x, 18699954.
32. Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007, 22:51-55.
33. Lambert M, Schimmelmann BG, Naber D, Eich FX, Schulz H, Huber CG, Karow A. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 2009, 42:277-283. 10.1055/s-0029-1234105, 19924588.
34. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41:125-128. 10.1055/s-2008-1076729, 18651339.
35. Karow A, Naber D, Lambert M, Moritz S, . EGOFORS Initiative Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry 2012, 27:401-405. 10.1016/j.eurpsy.2011.01.012, 21570262, EGOFORS Initiative.
36. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Text Revision 2000, 817-818. Arlington: American Psychiatric Association, American Psychiatric Association.
37. Llorca PM, Lançon C, Lancrenon S, Bayle FJ, Caci H, Rouillon F, Gorwood P. The " Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire. Schizophr Res 2009, 113:218-225. 10.1016/j.schres.2009.04.029, 19464855.
38. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771. 10.1001/archpsyc.1976.01770060086012, 938196.
39. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
40. Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry 2011, 10:18. 10.1186/1744-859X-10-18, 3132204, 21702932.
41. Balanzá V, Bobes J, Fernando C, García P, Martinez MR, Olivares JM, Rodríguez A, Herrero MS, San L. La funcionalidad en el paciente con trastorno mental grave: una encuesta de opinion entre psiquiatras españoles. Rev Psiquiatr Salud Ment (Barc) 2011, 4(Suppl 1):1-8.
42. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 2007, 93:160-168. 10.1016/j.schres.2007.01.014, 17395430.
43. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007, 94:99-106. 10.1016/j.schres.2006.12.032, 17499480.
44. Peuskens J, Gorwood P, . EGOFORS Initiative How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur Psychiatry 2011, 27:391-395. EGOFORS Initiative.
45. Schaub D, Brüne M, Jaspen E, Pajonk FG, Bierhoff HW, Juckel G. The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci 2011, 261:85-93. 10.1007/s00406-010-0122-1, 20652295.
46. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004, 18(Suppl 2):5-17.
47. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012, 27:432-436. 10.1016/j.eurpsy.2011.02.015, 21602034.
48. Figueira ML, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr Opin Psychiatry 2011, 24:91-99.